HEALTHCARE ANALYTICS

Carbon Health Announces Best-in-Class Patient Outcomes from Diabetes Program

Carbon Health | December 01, 2022 | Read time : 04:00 min

Carbon Health

In honor of National Diabetes Awareness Month in November, Carbon Health, a hybrid healthcare company that combines expert care with proprietary technology for easy everyday health, announces compelling new patient outcomes from its innovative diabetes program. To date, Carbon Health's diabetes program has helped two-thirds of its patients with uncontrolled diabetes achieve and maintain recommended glycemic targets, while patients with baseline A1c >9.0% in particular saw an impressive average A1c reduction of 4.2%.

Carbon Health’s program is endocrinologist-led, integrated with primary care, and supported by a team of certified diabetes educators. It is also completely virtual, making it easily accessible to patients with no waiting or travel time involved. The Carbon Health electronic health record integrates data from continuous glucose monitors into the patient’s chart and enables seamless care coordination among all members of the care team. Patients are able to log meals and medications alongside their CGM data in the Carbon Health patient app, which is an everyday companion to their care.

Diabetes care traditionally involves fingerstick glucose monitoring and quarterly visits. We’re flipping that on its head with our measurement-based, personalized, and proactive diabetes program. We’re the only healthcare provider to integrate a combination of blood glucose data from a CGM device with food, physical activity, and medication into our electronic health record (EHR) to allow patients and their interdisciplinary care teams – including primary care providers – to have incredibly powerful insights at their fingertips. This continuous data better enables our care team to manage our patients virtually and offer proactive support when they need it the most, avoiding one-size-fits-all advice and broken handoffs.”

Myoung Cha, Chief Strategy Officer at Carbon Health

These new outcomes will be presented at the 16th International Conference on Advanced Technologies & Treatments for Diabetes and represent best-in-class results among a number of diabetes care solutions. A recent analysis of 204 patients in the program found that 66.8% with baseline A1c ≥7.0% are meeting the guideline-recommended 70% time in range in their latest four weeks of available CGM data. Meanwhile, 54.0% of this cohort reached 70% time in range in their first 4 weeks of participating in the program then maintained that target thereafter, indicating that glycemic control was achieved rapidly and effectively. Among patients with baseline A1c >9.0%, Carbon Health's diabetes program lowered A1c by an average of 4.2%, compared to 3.3% by a leading digital diabetes competitor.

Additionally, Carbon Health has made the following enhancements to its diabetes program

 

  • Meal rankings: This unique feature shows the connection between meals and blood sugar changes, helping patients to better understand on their own which meals they should favor or avoid/limit.
  • Peer support: Diabetes care & education specialists facilitate peer support and open discussions through virtual group learning sessions.
  • Educational content: Expanding the diabetes content library to increase patient knowledge includes offering an evidence-based comparison of popular diets and strategies for eating healthy on the road.
  • Ongoing accountability: Carbon Health’s care team has developed bi-weekly notifications to support patients: celebrating when they reach their blood sugar goals and reaching out when they need help. The notifications also act as time-saving tools for providers, who can easily see changes and better drive care adherence.

 

For those at higher risk of diabetes, including individuals with high blood pressure, high cholesterol and/or a family history of diabetes, Carbon Health also offers an improved metabolic health assessment in California. Due to the complete integration of CGM data with the Carbon Health app as well as meal rankings, the metabolic insights program now offers even more individualized and actionable insights so patients can see what works and make appropriate lifestyle shifts. Learn more and check eligibility for the metabolic insights program here.

Diabetes and metabolic care at Carbon Health illustrate the company’s innovative care delivery model, Connective Care. Where typical primary care is anchored in a visit, Carbon Health combines technology and expert care so every patient can establish a relationship with their own integrated team, monitor and manage their health on the go, and access in-person care when and where they need it.

“We’re proud of the outcomes that are driving real change for our patients. It’s truly only by leveraging this integrated primary care model that we are able to offer our patients care that is simple, flexible, and personal,” said Dr. Calvin Wu, Medical Director of the diabetes program and endocrinologist at Carbon Health.

About Carbon Health
Carbon Health is a modern healthcare company offering hybrid care for easier everyday health. By combining custom technology with expert care, Carbon Health enables patients to establish a direct relationship with an integrated team, monitor and manage their health on the go, and access in-person care when and where they need it.

Building on the success of its nationwide urgent care network, Carbon Health treats the full spectrum of first-contact needs – from acute issues to chronic conditions, as well as ongoing physical and mental health needs. The company is also expanding into value-based care through work with employers, health plans, health systems, and other ecosystem partners.

 

Spotlight

Many of our customers want to know more about provider quality and cost-efficiency. To help provide Cigna customers with relevant information to make their own health care decisions, we evaluate provider quality and cost-efficiency information at the specialty level by using a methodology consistent with national standards and incorporating provider feedback on contracted providers in 21 specialty types. In addition, groups who meet Cigna’s specific quality and cost-efficiency criteria can receive the Cigna Care Designation (CCD) which may also be utilized as part of a tiered benefit plan option. This whitepaper explains the methodology used to measure the quality and cost-efficiency results of individual providers at the specialty level and how the criteria are met for a group to achieve CCD, as well as provide details regarding the profile information used on the provider directory displays.

Spotlight

Many of our customers want to know more about provider quality and cost-efficiency. To help provide Cigna customers with relevant information to make their own health care decisions, we evaluate provider quality and cost-efficiency information at the specialty level by using a methodology consistent with national standards and incorporating provider feedback on contracted providers in 21 specialty types. In addition, groups who meet Cigna’s specific quality and cost-efficiency criteria can receive the Cigna Care Designation (CCD) which may also be utilized as part of a tiered benefit plan option. This whitepaper explains the methodology used to measure the quality and cost-efficiency results of individual providers at the specialty level and how the criteria are met for a group to achieve CCD, as well as provide details regarding the profile information used on the provider directory displays.

Related News

FUTURE OF HEALTHCARE

Anumana and Pfizer Partner to Enable Early Detection of Underdiagnosed Cardiovascular Disease

Anumana | December 16, 2022

Anumana, Inc., an AI-driven health technology company and portfolio company of nference, has entered into a multi-year agreement with Pfizer, Inc. for Anumana to develop an artificial intelligence electrocardiogram algorithm designed to enable the early suspicion of cardiac amyloidosis. Anumana will conduct a clinical validation trial and pursue De Novo classification for the algorithm as a Software-as-a-Medical-Device and aims to gain regulatory approval for the algorithm as an SaMD for the detection of cardiac amyloidosis in the U.S., Europe and Japan. Cardiac amyloidosis is a serious, progressive, and underdiagnosed rare disease that leads to heart failure.1 In patients with cardiac amyloidosis, the heart walls become stiff, making it difficult for the left ventricle to properly relax and fill with blood, while at the same time hampering its ability to squeeze and pump blood out of the heart. Symptoms and comorbidities associated with cardiac amyloidosis, such as shortness of breath, knee pain, bilateral carpal tunnel syndrome, kidney disease, and gastrointestinal issues, can vary and seem unrelated, making diagnosis difficult.2,3 “The challenge in diagnosing cardiac amyloidosis can prevent patients from getting treatment while the disease continues to progress. We believe this collaboration will demonstrate the power of Anumana’s AI-ECG algorithms to help clinicians intervene earlier, giving them greater ability to improve patient outcomes and prolong lives.” David McMullin, chief business officer of Anumana The research agreement with Pfizer will help deepen Anumana’s efforts to implement AI-enabled early detection software that can reveal signals from ECGs that humans cannot interpret. The ubiquitous nature of the painless, non-invasive 100-year-old ECG test gives AI-ECG algorithms the potential to reach a larger number of patients earlier. “AI-ECG solutions alert clinicians to humanly imperceptible patterns in ECG signals, providing an early warning for serious occult or impending disease,” said Paul Friedman, M.D., Chair of the Department of Cardiovascular Medicine at Mayo Clinic and Chair of Anumana’s Mayo Clinic Board of Advisors. “This stands to improve the lives of people with cardiac amyloidosis by improving the speed of triage and care of this group.” Anumana was founded in 2021 in collaboration with the Mayo Clinic Platform. Anumana has licensed Mayo Clinic AI-ECG algorithms for low ejection fraction, pulmonary hypertension, and hyperkalemia, all of which have received Breakthrough Device Designation from the U.S. FDA. These algorithms have been validated by over 75 peer-reviewed publications, including a first of its kind prospective clinical impact study on low ventricular ejection fraction that was published in Nature Medicine in 2021, and another first of its kind batch enrolled prospective clinical impact study that demonstrated the effectiveness of AI-ECG to screen for undetected atrial fibrillation in normal sinus rhythm that was published in The Lancet in 2022. About Anumana Anumana, an AI-driven health technology company and portfolio company of nference, is harnessing industry-leading AI and translational science to unlock the electrical language of the heart as never before. Anumana algorithms have been developed, trained, and validated using clinical data from Mayo Clinic and other leading institutions to detect hidden diseases using AI-ECG algorithms and to enhance and improve interventional procedures through real-time AI techniques. Multiple Anumana algorithms have received FDA Breakthrough Device Designation and are currently undergoing rigorous clinical trial validation. Anumana software devices are designed for real-world physician use, integrating into existing workflows at the point of care to reduce costs and enhance quality of life. Anumana algorithms are investigational medical devices and have not yet received regulatory approval or clearance.

Read More

HEALTH TECHNOLOGY, FUTURE OF HEALTHCARE

Compulink Receives 21st Century Cures Act Certification From ONC

Compulink Healthcare Solutions | January 03, 2023

As the market leader in specialty-specific, all-in-one EHR solutions, Compulink Healthcare Solutions has earned the ONC-Health IT 2015 Edition Cures Update Health IT certification that will come into effect in 2023. This includes the most recent interoperability standards essential for supporting compliance with the information-sharing requirements of the 21st Century Cures Act. Compulink said that getting certified early shows how committed they are to making sure that their clients' solutions are in line with the many rules that require the use of certified EHR technology. Compulink Advantage™ is an all-in-one database EHR solution that provides its clients with practice management, inventory management, patient portal, mobile patient engagement, ASC, E-Commerce, analytics, optical POS (for eyecare practices), and a billing (RCM) service option. The company offers complete EHR solutions for ophthalmology, optometry, orthopedics, otolaryngology, behavioral health, dermatology, gastroenterology, podiatry, pain management, physical therapy, audiology, and urology. Drummond Group LLC, an authorized certification body, certified Compulink's EHR products (ACB). Drummond, testing for more than 20 years, has done more than 3,000 tests and certifications for health IT since 2010. About the Certification Compulink Advantage Version 12 complies with the 2015 Edition. It has been approved as such by an ONC-ACB based on the criteria for certification set by the Secretary of Health and Human Services. This certification does not mean that the United States Department of Health and Human Services backs the product or service in question. About theCompulink Healthcare Solutions Compulink Healthcare Solutions all-in-one EHR and practice management solution has helped specialty medical practices reduce costs, increase efficiency, and simplify the delivery of excellent patient care. Compulink is the leader in fully customizable EHR solutions that adapt to your practice style and is used by over 26,000 providers in over 4,700 locations, 70 ambulatory surgical centers, and 19 colleges and universities.

Read More

FUTURE OF HEALTHCARE, HEALTHCARE ANALYTICS

Stericycle Completes Divestiture of Communication Solutions Business to Carenet Health

Stericycle, Inc. | December 05, 2022

Stericycle, Inc. a leading provider of regulated medical waste management and secure information destruction solutions, announced that it has completed the divestiture of its Communication Solutions business to Carenet Health, one of the healthcare industry’s leading consumer engagement and telehealth partners, for approximately $45 million in cash, subject to customary adjustments. Stericycle intends to use the net proceeds from the divestiture to pay down outstanding debt. Stericycle Communication Solutions provides online scheduling, automated messaging and strategic inbound and outbound call center services to drive patient access, action and adherence. For the nine months ended September 30, 2022, the Communication Solutions business had revenues of approximately $45 million, reported in the North America segment, as part of Regulated Waste and Compliance Services revenues. In connection with the closing, Stericycle and Carenet Health entered into a purchase and transition services agreements. The divested business includes approximately 500 team members in North America. “The sale of Stericycle Communication Solutions demonstrates our continued commitment to deliver on our portfolio optimization key business priority, marking our eleventh divestiture since 2019. By further streamlining our company, we are taking another step in our journey to focus on our core businesses and improve sustainable operational efficiencies. I would like to thank our team members transitioning to Carenet Health and wish them much success as they work to deliver better experiences and outcomes across the patient journey." Cindy J. Miller, chief executive officer of Stericycle About Carenet Health Carenet Health is one of the healthcare industry’s leading consumer engagement and telehealth partners—providing consumer engagement, clinical support, virtual care and advocacy solutions on behalf of 250+ of the nation’s premier health plans, providers, health systems and Fortune 500 companies. One in four Americans have access to Carenet’s services. Carenet is headquartered in San Antonio, Texas, with additional office locations in New Mexico, Maine and the Philippines. About Stericycle Stericycle, Inc., is a U.S. based business-to-business services company and leading provider of compliance-based solutions that protects people and brands, promotes health and well-being, and safeguards the environment. Stericycle serves customers in the U.S. and 16 countries with solutions for regulated waste and compliance services and secure information destruction.

Read More